| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 19 | 2024 | 23 | 3.230 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 30 | 2023 | 35 | 3.140 |
Why?
|
| Vasculitis | 22 | 2022 | 49 | 2.480 |
Why?
|
| Immunosuppressive Agents | 18 | 2024 | 291 | 2.330 |
Why?
|
| Glomerulonephritis | 14 | 2024 | 30 | 2.260 |
Why?
|
| Kidney Failure, Chronic | 20 | 2022 | 188 | 1.870 |
Why?
|
| Peroxidase | 14 | 2024 | 69 | 1.670 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 8 | 2023 | 11 | 1.550 |
Why?
|
| Cyclophosphamide | 12 | 2023 | 69 | 1.290 |
Why?
|
| Lupus Nephritis | 7 | 2022 | 31 | 1.120 |
Why?
|
| Kidney | 13 | 2023 | 391 | 1.090 |
Why?
|
| Myeloblastin | 12 | 2023 | 14 | 1.070 |
Why?
|
| Kidney Diseases | 5 | 2021 | 157 | 0.910 |
Why?
|
| Kidney Transplantation | 9 | 2023 | 257 | 0.900 |
Why?
|
| Nephrotic Syndrome | 3 | 2021 | 7 | 0.900 |
Why?
|
| Glomerulonephritis, Membranous | 7 | 2023 | 14 | 0.800 |
Why?
|
| Granulomatosis with Polyangiitis | 6 | 2023 | 14 | 0.730 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2024 | 112 | 0.700 |
Why?
|
| Glucocorticoids | 6 | 2016 | 170 | 0.670 |
Why?
|
| Middle Aged | 62 | 2024 | 16197 | 0.630 |
Why?
|
| Adult | 57 | 2024 | 15681 | 0.600 |
Why?
|
| Churg-Strauss Syndrome | 4 | 2023 | 14 | 0.570 |
Why?
|
| Aged | 50 | 2023 | 13267 | 0.540 |
Why?
|
| Humans | 96 | 2024 | 59079 | 0.540 |
Why?
|
| Male | 69 | 2024 | 27399 | 0.530 |
Why?
|
| Plasmapheresis | 2 | 2013 | 18 | 0.510 |
Why?
|
| Female | 68 | 2024 | 30712 | 0.500 |
Why?
|
| Risk Factors | 28 | 2024 | 4991 | 0.480 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 38 | 0.460 |
Why?
|
| Apolipoprotein L1 | 3 | 2023 | 6 | 0.460 |
Why?
|
| Albuminuria | 3 | 2012 | 23 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 113 | 0.450 |
Why?
|
| Silicon Dioxide | 2 | 2007 | 59 | 0.450 |
Why?
|
| Nephrosis, Lipoid | 4 | 2020 | 6 | 0.450 |
Why?
|
| Spouses | 2 | 2015 | 38 | 0.440 |
Why?
|
| Prednisone | 1 | 2013 | 79 | 0.440 |
Why?
|
| Adolescent | 22 | 2024 | 5897 | 0.440 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 150 | 0.430 |
Why?
|
| Renal Dialysis | 9 | 2016 | 184 | 0.410 |
Why?
|
| Recurrence | 12 | 2023 | 575 | 0.380 |
Why?
|
| Remission Induction | 8 | 2016 | 135 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 60 | 0.360 |
Why?
|
| Occupational Diseases | 2 | 2015 | 264 | 0.340 |
Why?
|
| Mycophenolic Acid | 5 | 2014 | 32 | 0.340 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 151 | 0.330 |
Why?
|
| Young Adult | 16 | 2024 | 4303 | 0.330 |
Why?
|
| Occupational Exposure | 2 | 2015 | 303 | 0.330 |
Why?
|
| Time Factors | 14 | 2020 | 3554 | 0.320 |
Why?
|
| Autoantigens | 6 | 2023 | 125 | 0.320 |
Why?
|
| North Carolina | 8 | 2016 | 65 | 0.320 |
Why?
|
| Retrospective Studies | 16 | 2024 | 5952 | 0.320 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 95 | 0.310 |
Why?
|
| Child | 13 | 2024 | 4260 | 0.310 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 532 | 0.310 |
Why?
|
| Calcineurin Inhibitors | 4 | 2016 | 22 | 0.300 |
Why?
|
| Autoimmune Diseases | 6 | 2024 | 222 | 0.300 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2024 | 194 | 0.300 |
Why?
|
| Prescription Drugs | 2 | 2022 | 50 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2021 | 37 | 0.280 |
Why?
|
| Prognosis | 9 | 2022 | 1563 | 0.280 |
Why?
|
| Glomerulonephritis, IGA | 3 | 2020 | 7 | 0.270 |
Why?
|
| Case-Control Studies | 11 | 2019 | 1054 | 0.270 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 156 | 0.270 |
Why?
|
| Epitopes | 3 | 2019 | 299 | 0.270 |
Why?
|
| Quality of Life | 3 | 2012 | 1103 | 0.270 |
Why?
|
| Biopsy | 7 | 2022 | 373 | 0.260 |
Why?
|
| Disease Progression | 6 | 2023 | 1038 | 0.260 |
Why?
|
| Communicable Diseases | 2 | 2020 | 81 | 0.260 |
Why?
|
| Kidney Glomerulus | 3 | 2017 | 19 | 0.260 |
Why?
|
| Hypertension | 4 | 2023 | 598 | 0.250 |
Why?
|
| Child, Preschool | 6 | 2024 | 1824 | 0.250 |
Why?
|
| B-Lymphocytes | 3 | 2015 | 550 | 0.250 |
Why?
|
| Neutrophils | 3 | 2020 | 351 | 0.240 |
Why?
|
| Pesticides | 2 | 2015 | 55 | 0.240 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 9 | 0.240 |
Why?
|
| Genotype | 8 | 2023 | 642 | 0.240 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2024 | 18 | 0.240 |
Why?
|
| Incidence | 6 | 2020 | 1232 | 0.230 |
Why?
|
| CD5 Antigens | 2 | 2015 | 18 | 0.230 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2014 | 4 | 0.230 |
Why?
|
| Autoantibodies | 5 | 2024 | 174 | 0.230 |
Why?
|
| Aged, 80 and over | 14 | 2013 | 5062 | 0.220 |
Why?
|
| Autoimmunity | 2 | 2024 | 223 | 0.220 |
Why?
|
| Infertility | 1 | 2024 | 33 | 0.220 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 337 | 0.220 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 35 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 459 | 0.210 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 47 | 0.210 |
Why?
|
| Leukocytes | 2 | 2014 | 107 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2023 | 2430 | 0.210 |
Why?
|
| Proteinuria | 5 | 2022 | 37 | 0.210 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 675 | 0.200 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 7 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2012 | 738 | 0.200 |
Why?
|
| Anticholesteremic Agents | 3 | 2007 | 34 | 0.200 |
Why?
|
| Smoking | 1 | 2007 | 831 | 0.190 |
Why?
|
| Podocytes | 1 | 2021 | 8 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 139 | 0.190 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 1208 | 0.180 |
Why?
|
| Prevalence | 5 | 2024 | 1278 | 0.180 |
Why?
|
| United States | 11 | 2023 | 7461 | 0.180 |
Why?
|
| Obesity | 2 | 2024 | 1185 | 0.170 |
Why?
|
| Survival Rate | 4 | 2015 | 788 | 0.170 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2019 | 5 | 0.170 |
Why?
|
| Complement C5a | 1 | 2019 | 5 | 0.170 |
Why?
|
| Complement Factor B | 1 | 2019 | 11 | 0.170 |
Why?
|
| Complement C3a | 1 | 2019 | 8 | 0.170 |
Why?
|
| Systemic Vasculitis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Mice, Knockout | 1 | 2024 | 1988 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2013 | 255 | 0.160 |
Why?
|
| Rituximab | 5 | 2023 | 82 | 0.160 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 89 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2056 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2024 | 3080 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2016 | 5129 | 0.150 |
Why?
|
| Thyroid Diseases | 2 | 2007 | 26 | 0.150 |
Why?
|
| Surveys and Questionnaires | 9 | 2015 | 2571 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2014 | 1466 | 0.140 |
Why?
|
| Heptanoic Acids | 2 | 2007 | 20 | 0.140 |
Why?
|
| Caregivers | 1 | 2019 | 216 | 0.140 |
Why?
|
| Infant | 4 | 2017 | 1518 | 0.130 |
Why?
|
| Hospitalization | 2 | 2020 | 1274 | 0.130 |
Why?
|
| Alleles | 3 | 2014 | 425 | 0.130 |
Why?
|
| Pyrroles | 2 | 2007 | 49 | 0.130 |
Why?
|
| Hematinics | 2 | 2014 | 10 | 0.130 |
Why?
|
| Sex Factors | 5 | 2011 | 957 | 0.130 |
Why?
|
| Ethylene Glycol | 1 | 2015 | 7 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2019 | 154 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 673 | 0.130 |
Why?
|
| Antibody Specificity | 2 | 2013 | 99 | 0.130 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2015 | 29 | 0.130 |
Why?
|
| Farmers | 1 | 2015 | 18 | 0.130 |
Why?
|
| Poisoning | 1 | 2015 | 29 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 238 | 0.130 |
Why?
|
| Agriculture | 1 | 2015 | 28 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 139 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 1022 | 0.120 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 167 | 0.120 |
Why?
|
| Serum Albumin | 5 | 2016 | 38 | 0.120 |
Why?
|
| Creatinine | 5 | 2022 | 121 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 1518 | 0.120 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 62 | 0.120 |
Why?
|
| Risk Assessment | 6 | 2020 | 1902 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 273 | 0.120 |
Why?
|
| HLA-DR Antigens | 2 | 2011 | 27 | 0.110 |
Why?
|
| Sickle Cell Trait | 1 | 2014 | 7 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 204 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 158 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 30 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 826 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 12 | 0.110 |
Why?
|
| Patient Selection | 2 | 2013 | 443 | 0.110 |
Why?
|
| Neoplasms | 1 | 2023 | 1224 | 0.110 |
Why?
|
| Apolipoproteins | 2 | 2023 | 16 | 0.110 |
Why?
|
| Histones | 1 | 2016 | 463 | 0.110 |
Why?
|
| Information Dissemination | 2 | 2011 | 114 | 0.110 |
Why?
|
| Rural Population | 2 | 2015 | 190 | 0.100 |
Why?
|
| Glucuronides | 2 | 2009 | 7 | 0.100 |
Why?
|
| Health Education | 2 | 2011 | 184 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1017 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 213 | 0.100 |
Why?
|
| Health Transition | 1 | 2012 | 5 | 0.100 |
Why?
|
| Social Participation | 1 | 2012 | 14 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2012 | 103 | 0.100 |
Why?
|
| Friends | 1 | 2012 | 29 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2013 | 169 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 172 | 0.100 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2011 | 14 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 34 | 0.100 |
Why?
|
| Neutrophil Activation | 2 | 2020 | 24 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2012 | 145 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2008 | 188 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2009 | 731 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2013 | 351 | 0.090 |
Why?
|
| Internet | 2 | 2012 | 455 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 87 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 925 | 0.090 |
Why?
|
| Graft Survival | 2 | 2021 | 278 | 0.090 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 76 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2011 | 37 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2317 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1444 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 100 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 11 | 0.090 |
Why?
|
| Pilot Projects | 5 | 2014 | 915 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 66 | 0.090 |
Why?
|
| Gene Expression | 3 | 2020 | 805 | 0.090 |
Why?
|
| Health Surveys | 2 | 2012 | 306 | 0.090 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 68 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2022 | 200 | 0.080 |
Why?
|
| Losartan | 1 | 2009 | 18 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 564 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2013 | 485 | 0.080 |
Why?
|
| Registries | 4 | 2016 | 802 | 0.080 |
Why?
|
| Perception | 1 | 2010 | 178 | 0.080 |
Why?
|
| Plasminogen | 1 | 2008 | 7 | 0.080 |
Why?
|
| Steroids | 2 | 2013 | 54 | 0.080 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 9 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2009 | 201 | 0.080 |
Why?
|
| Medicare | 2 | 2023 | 601 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 105 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2016 | 553 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2024 | 304 | 0.080 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 18 | 0.080 |
Why?
|
| Phenotype | 4 | 2015 | 1153 | 0.070 |
Why?
|
| Health Status | 1 | 2011 | 448 | 0.070 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 18 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 172 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2008 | 48 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2013 | 276 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2012 | 482 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2007 | 85 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 25 | 0.070 |
Why?
|
| North America | 2 | 2020 | 109 | 0.070 |
Why?
|
| Cotinine | 1 | 2007 | 18 | 0.070 |
Why?
|
| Spleen | 2 | 2024 | 485 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 402 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 58 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2009 | 519 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2007 | 51 | 0.070 |
Why?
|
| Serine Endopeptidases | 2 | 2004 | 77 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 322 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2015 | 837 | 0.070 |
Why?
|
| Cholestyramine Resin | 1 | 2005 | 1 | 0.070 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2005 | 6 | 0.060 |
Why?
|
| Anemia | 1 | 2007 | 117 | 0.060 |
Why?
|
| Iowa | 2 | 2015 | 20 | 0.060 |
Why?
|
| Health Promotion | 1 | 2010 | 490 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2008 | 276 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2451 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2005 | 39 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 56 | 0.060 |
Why?
|
| Prodrugs | 1 | 2005 | 32 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 244 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2007 | 297 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2007 | 316 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 49 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 249 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2024 | 145 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2024 | 891 | 0.060 |
Why?
|
| Nicaragua | 1 | 2023 | 16 | 0.060 |
Why?
|
| Mice | 4 | 2024 | 10235 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 291 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 957 | 0.060 |
Why?
|
| Transplant Recipients | 1 | 2023 | 31 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 69 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2019 | 1577 | 0.050 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2002 | 28 | 0.050 |
Why?
|
| Living Donors | 1 | 2003 | 64 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 609 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 102 | 0.050 |
Why?
|
| HLA-DP beta-Chains | 1 | 2022 | 2 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 433 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1536 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2023 | 139 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 351 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2003 | 132 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2003 | 163 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 180 | 0.050 |
Why?
|
| Animals | 5 | 2024 | 19557 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2002 | 309 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 44 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 675 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2013 | 667 | 0.050 |
Why?
|
| Dust | 1 | 2001 | 39 | 0.050 |
Why?
|
| Drug Information Services | 2 | 2011 | 5 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2012 | 131 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2012 | 128 | 0.050 |
Why?
|
| Self Care | 2 | 2013 | 211 | 0.040 |
Why?
|
| Nephrology | 1 | 2000 | 14 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 418 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 1540 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 182 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 2 | 2011 | 12 | 0.040 |
Why?
|
| Complement C4 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Biomarkers | 3 | 2013 | 1202 | 0.040 |
Why?
|
| Properdin | 1 | 2019 | 14 | 0.040 |
Why?
|
| Focus Groups | 2 | 2012 | 290 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 469 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2000 | 146 | 0.040 |
Why?
|
| Life Style | 2 | 2012 | 328 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2094 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 654 | 0.040 |
Why?
|
| Social Support | 2 | 2012 | 357 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1128 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1247 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 696 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 276 | 0.040 |
Why?
|
| Antibodies | 2 | 2008 | 176 | 0.040 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2017 | 5 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2017 | 24 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1123 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1220 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3183 | 0.030 |
Why?
|
| Acylation | 1 | 2016 | 15 | 0.030 |
Why?
|
| Length of Stay | 1 | 2000 | 761 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 607 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2351 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 126 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 43 | 0.030 |
Why?
|
| Poison Control Centers | 1 | 2015 | 6 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 2015 | 8 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 2015 | 14 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 32 | 0.030 |
Why?
|
| Acidosis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Herbicides | 1 | 2015 | 18 | 0.030 |
Why?
|
| Occupations | 1 | 2015 | 52 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1092 | 0.030 |
Why?
|
| Cholesterol | 2 | 2007 | 256 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 101 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2013 | 6 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 384 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 36 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 349 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 50 | 0.030 |
Why?
|
| Uncertainty | 1 | 2013 | 32 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 73 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 450 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 807 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 89 | 0.030 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 350 | 0.030 |
Why?
|
| Systems Biology | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 4 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 117 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 193 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 25 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 102 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 70 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 191 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 119 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2012 | 254 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 76 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 87 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 103 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 237 | 0.020 |
Why?
|
| Online Systems | 1 | 2011 | 20 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 232 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 217 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 280 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 284 | 0.020 |
Why?
|
| Comprehension | 1 | 2012 | 126 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 389 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 53 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 257 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 324 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 219 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 353 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 480 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 847 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Information Seeking Behavior | 1 | 2009 | 35 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 102 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 307 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 26 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 197 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 567 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 207 | 0.020 |
Why?
|
| France | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cell Count | 1 | 2008 | 128 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2008 | 24 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2008 | 20 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 455 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2007 | 8 | 0.020 |
Why?
|
| Glycosuria | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2007 | 21 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2007 | 22 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1904 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 38 | 0.020 |
Why?
|
| Hematuria | 1 | 2007 | 18 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2008 | 48 | 0.020 |
Why?
|
| Communication | 1 | 2012 | 531 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 229 | 0.020 |
Why?
|
| Decision Making | 1 | 2011 | 384 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2008 | 173 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ferrous Compounds | 1 | 2007 | 11 | 0.020 |
Why?
|
| Kidney Tubules, Distal | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 11 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2007 | 34 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2007 | 18 | 0.020 |
Why?
|
| Professional Role | 1 | 2007 | 37 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 99 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 515 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 381 | 0.020 |
Why?
|
| Iron | 1 | 2007 | 144 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 770 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2007 | 123 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 446 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 139 | 0.020 |
Why?
|
| Program Development | 1 | 2007 | 210 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2007 | 144 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 856 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2005 | 36 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2005 | 29 | 0.020 |
Why?
|
| Pharmacists | 1 | 2007 | 123 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 737 | 0.020 |
Why?
|
| Physicians | 1 | 2011 | 429 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 542 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2005 | 54 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 846 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 489 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 344 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 2004 | 53 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2003 | 30 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2003 | 43 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 683 | 0.010 |
Why?
|
| Triglycerides | 1 | 2005 | 245 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 519 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 865 | 0.010 |
Why?
|
| Particle Size | 1 | 2005 | 394 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 12 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1034 | 0.010 |
Why?
|
| Superoxides | 1 | 2002 | 69 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 250 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2002 | 43 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 44 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 453 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 2886 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 148 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 473 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 188 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 1100 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 275 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 656 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 907 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 436 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 686 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 839 | 0.010 |
Why?
|